.
MergerLinks Header Logo

New Deal


Announced

Completed

Waypoint Capital completed the acquisition of a 70% stake in Allergy Partners.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For70%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Friendly

allergy treatment

Private Equity

Cross Border

Majority

Private

asthma

United States

Health Care Services

Acquisition

Completed

Synopsis

Edit

Waypoint Capital, an entrepreneurial private investment firm, completed the acquisition of a 70% stake in Allergy Partners, the largest US group of single-specialty allergy and asthma practices. Financial terms were not disclosed. "We are excited to be partnering with Waypoint Capital as Allergy Partners looks to increase access to our services for even more patients across the country. Our mission is to be leaders in the development and delivery of high-quality health care for patients with asthma and allergic disease. Our partnership with Waypoint will further that mission as we continue to execute on our strategic initiatives, further build our vast care network, and promote continued research and innovation in the field of allergy and asthma care," David Brown, Allergy Partners CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US